Edition:
United States

Newron Pharmaceuticals SpA (NWRN.S)

NWRN.S on Swiss Exchange

21.30CHF
26 May 2017
Change (% chg)

CHF-0.80 (-3.62%)
Prev Close
CHF22.10
Open
CHF22.60
Day's High
CHF22.80
Day's Low
CHF20.95
Volume
81,880
Avg. Vol
70,537
52-wk High
CHF28.70
52-wk Low
CHF13.85

Latest Key Developments (Source: Significant Developments)

Newron Pharmaceuticals: Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago in Canada
Tuesday, 11 Apr 2017 02:07am EDT 

Newron Pharmaceuticals Spa :Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada.  Full Article

Newron Pharmaceuticals: XADAGO to be introduced in Portugal
Monday, 10 Apr 2017 01:18am EDT 

Newron Pharmaceuticals S.p.A. :ZAMBON S.p.A., and partner Newron Pharmaceuticals S.p.A., introduce XADAGO (Safinamide) for patients in the middle to late stage of Parkinson's disease in Portugal.  Full Article

Newron Pharmaceuticals says FDA approves Xadago for Parkinson's disease patients
Tuesday, 21 Mar 2017 02:30pm EDT 

Newron Pharmaceuticals SpA : FDA approves Xadago (safinamide) for parkinson's disease (PD) patients . Announced FDA approved use of Xadago for treatment of Parkinson's disease as add-on therapy to Levodopa/Carbidopa .Will now accelerate U.S. launch preparations for Xadago.  Full Article

Newron Pharmaceuticals FY net loss shrinks to EUR 15.2 mln
Thursday, 2 Mar 2017 01:12am EST 

Newron Pharmaceuticals Spa : Total revenues have substantially increased to 6.7 million euros ($7.06 million) from 2.4 million euros in 2015 in the reporting period . Says FY cash used in operations has increased to 19.6 million euros (2015: 12.9 million euros) .FY net loss at 15.2 million euros versus 22.8 million euros year ago.  Full Article

Newron: Seqirus and Zambon enter into a partnership for parkinson’s disease product in Australia and New Zealand
Tuesday, 10 Jan 2017 11:37am EST 

Newron Pharmaceuticals SpA :Seqirus and Zambon enter into a partnership for parkinson’s disease product in Australia and New Zealand.  Full Article

Newron Pharmaceuticals raises CHF 26.1 mln in a private placement of new shares
Friday, 7 Oct 2016 01:01am EDT 

Newron Pharmaceuticals Spa : Raises 26.1 million Swiss francs ($26.58 million) in a private placement of new shares .Has placed 1,320,530 new shares with institutional investors at a subscription price of 19.75 Swiss francs per share.  Full Article

Newron Pharmaceuticals launches private placement of new shares
Thursday, 6 Oct 2016 11:32am EDT 

Newron Pharmaceuticals SpA : Launches private placement of new shares . Up to 10 pct of the company's share capital .Intends to use the net proceeds of the issuance for general corporate purposes.  Full Article

Newron Pharmaceuticals re-submits US NDA for Xadago
Thursday, 22 Sep 2016 01:02am EDT 

Newron Pharmaceuticals Spa : Re-submits US New Drug Application for Xadago (safinamide) .As a class 2 resubmission, FDA is expected to complete its review of re-submission within 6 months of acceptance.  Full Article

Newron to re-submit US NDA for Xadago
Tuesday, 26 Jul 2016 01:01am EDT 

Newron Pharmaceuticals SpA : Newron prior regulatory filing for xadago (safinamide) in the US . Newron to re-submit US NDA for Xadago . FDA does not require further studies to misuse or dependence .Newron and the FDA agreed on the contents of the nda re-submission which newron expects to complete by November of this year.  Full Article

Newron Pharmaceuticals says Zambon introduces Xadago in Denmark and Sweden
Thursday, 28 Apr 2016 01:00am EDT 

Newron Pharmaceuticals SpA:Zambon introduces Xadago (Safinamide) for patients with mid- to late-stage parkinson's disease in Denmark and Sweden.  Full Article

More From Around the Web

BRIEF-Newron Pharmaceuticals receives 11.3 million euros milestone payments for US approval of Xadago

* RECEIVES EUR11.3M MILESTONE PAYMENTS FOR U.S. APPROVAL OF XADAGO (SAFINAMIDE) Source text for Eikon: Further company coverage: (Gdynia Newsroom)